• 목록
• 답변

In the domestic bio-industry, 'NRDO' is no longer an unfamiliar name. Their entry into KOSDAQ is also gradually increasing.

ARBORMED is also classified as NRDO, where external research institutes make profits from new drug candidates received from companies through clinical trials and technology transfers.
It is an independent platform established in the United States and is focusing on increasing business development (BD) efficiency.
Another point of differentiation is that it has a stable source of sales through generic drugs.

CEO Park Kyo-jin, who founded Arbomed in 2017, said, "The distinction is that there is ARBORMED U.S. subsidiaries (ARBORMED Pharmaceuticals) that sell clinical and licensed products in the U.S.,
starting with Generic, IMD, and new drugs," adding, "We want to serve as a bridge to Arbormed's own pipeline as well as helping the domestic pharmaceutical companies and biotech enter the U.S Market"
He explained, "The mission of Arbomed is derived from the name of an oak tree growing in Michigan, the U.S.A. called Arbor," and judged that it was suitable as a Biotech name that considers the patient's life.
In addition to CEO Park, Lim Won-bin, co-chairman of Dong-A ST's New Drug Research Institute, Vice President Han Won-sun, and Eun So-young, director of research and development (CDO),
are key executives of Arbormed.
After completing his MBA at the University of Michigan, CEO Park worked as a management consultant at the University of Michigan Hospital and co-founded MedCI (Santa Clara, California),
a new drug licensing consulting company that is the root of Arbormed, in 2004. Founded in April 2016, Arbormed's U.S. subsidiary has changed its governance structure so that the Arbormed Korean subsidiary,
which was created later, has a 100% stake.

CEO Park led about 30 new drug licensing deals in the 15 years since the founding of MedCI. A representative deal is the transfer of the original antibody-drug complex (ADC) technology signed by Lego Chem Bio
with Millennium, a 100% subsidiary of Japanese pharmaceutical company Takeda. The total contract size was 454.8 billion won. L/O, a $1 billion anticancer drug handed over by French state-run pharmaceutical
company LFB to TG Therapeutics in the U.S., and a $800 million license deal between Daiichi Sankyo in Japan and Genta, a U.S. bio company, also went through CEO Park's hands.

Currently, one of Arbormed's new drug pipelines is Wilson's disease treatment, which is classified as a rare disease. It is a rare and recessive genetic disease caused by a 1:300,000 chance due to a gene (atp7b) mutation
in the protein involved in copper metabolism. 50% of Wilson's disease patients develop chronic liver cirrhosis and 13% progress to acute severe liver cirrhosis. To date, the only treatment is a liver transplant.

Arbormed's Wilson disease treatment, introduced by Helmholtz Zentrum Munchen in Germany, is currently being developed as a copper discharge agent (vinegar injection) in a preclinical stage. It is a position
 that has confirmed a new mechanism of action that relieves symptoms of cirrhosis and binds to copper to quickly release it through bile. CEO Park said, "As a result of administering the treatment to 30 mice,
there were effects such as improving symptoms of cirrhosis and high copper affinity."

In the case of rare disease treatments, it is a disease with medical unmet needs and the number of globally competitive drugs is small, so we can expect rapid approval from the FDA,
he said. "We have formed a pipeline with drugs capable of global L/O in the early stages of clinical trials, including Wilson disease treatments." In the case of license transactions,
 it is more important to choose a company with expertise even if it is small than Big Pharma, which risks preserving the technology itself.

Experts point to securing sustainable sales sources as another strength of Arbormed. A case in point is the recent contract between IQU and the U.S. exclusive supply of
Parkinson's disease treatment (Rotigotin Patch). Arbormed secures profits through the possession of U.S. FDA approval and permission rights, drug price negotiations, complete imports,
 and distribution through wholesalers.

Two types of anticancer drugs contracted with Korea United Pharmaceutical and Fenmix's antibiotics are also in the form of Avomed's exclusive business in the United States.
CEO Park said, "We expect sales of these products, including the IQ patch system, to take place in the U.S. by 2023, and Avomed expects to generate about 100 billion won in sales."
 In contrast, many bio companies are covering R&D funds only through external funding without making money.

Arbormed is also planning to be listed on the KOSDAQ around 2023, when sales occur. The goal is to select the organizer in 2021 and apply for a technical evaluation in 2022.
Recently, SBI, Hana Financial Investment, Broadhill, Ion Asset Management, and Comes Investment have attracted 6 billion won in Series A investment. After the transaction, the valuation is about 33 billion won.